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Abstract 
We have studied the effects of corticosteroid treatment on the numbers of lymphocytes obtained from 
the spinal cords of Lewis rats with acute experimental autoimmune encephalomyelitis (EAE) induced 
by inoculation with myelin basic protein (MBP) and adjuvants. Flow cytometric studies showed that 
treatment with dexamethasone (4 mg/kg) 8–12 h prior to study on day 14 after inoculation resulted in a 
reduction in the numbers of CD5+, TCR + and V 8.2+ cells in the spinal cord. Limiting dilution 
analysis indicated that dexamethasone treatment 12 h prior to study on day 12 after inoculation reduced 
the frequencies of MBP-reactive and interleukin-2-responsive lymphocytes in the spinal cord to low 
levels, but reduced the frequency of concanavalin-A-responsive lymphocytes to a lesser extent. Using 
propidium iodide staining of nuclear chromatin we also studied lymphocyte apoptosis. Greater numbers 
of apoptotic cells were found in the cells extracted from the spinal cords of rats, examined on day 14, 
that had been treated 1–12 h previously with dexamethasone, than in saline-treated controls. This 
increased level of apoptosis was observed in the CD5+ and TCR + cell populations. At 1–4 h after 
dexamethasone treatment there was a reduction in the selective apoptosis of V 8.2+ cells that normally 
occurs during spontaneous recovery from EAE. Therefore apoptosis of V 8.2+ cells cannot explain the 
reduction in the numbers of V 8.2+ cells and MBP-reactive cells in the CNS after dexamethasone 
treatment. By 8–12 h after dexamethasone treatment the selectivity of the apoptotic process was 
restored. These studies suggest that a reduction in the number of T-lymphocytes in the central nervous 
system contributes to the beneficial effects of corticosteroids in EAE.  
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1. Introduction 
Experimental autoimmune encephalomyelitis (EAE) is mediated by CD4+ T-lymphocytes and 
can be induced in susceptible animals by active inoculation with myelin antigens and 
adjuvants or by the passive transfer of T-lymphocytes sensitized to these antigens. EAE is the 
best available animal model of multiple sclerosis. Recovery from EAE is associated with loss 
of T-lymphocytes from the central nervous system (CNS) (Matsumoto and Fujiwara, 1987; 
McCombe et al., 1992; Zeine and Owens, 1993) and apoptosis of these lymphocytes in the 
CNS (Pender et al., 1991 and Pender et al., 1992; Schmied et al., 1993). In the Lewis rat, the 
encephalitogenic lymphocytes in EAE induced by inoculation with myelin basic protein 
(MBP) (MBP–EAE) are predominantly V 8.2+ (Offner et al., 1993; Tsuchida et al., 1993; 
Imrich et al., 1995). In MBP–EAE induced by the passive transfer of V 8.2+ MBP-specific 
T-lymphocytes or by active inoculation with purified MBP and adjuvants, we have shown 
that the disease-relevant V 8.2+ MBP-reactive T-lymphocytes are selectively eliminated from 
the CNS by apoptosis (Tabi et al., 1994 and Tabi et al., 1995; McCombe et al., 1996). The 
aim of the present study was to determine whether exogenous corticosteroids, which are able 
to suppress the clinical signs of EAE and which are widely used in the treatment of multiple 
sclerosis, lead to a reduction in the number of V 8.2+ lymphocytes and MBP-reactive T-cells 
in the CNS in EAE, and whether this is associated with increased T-cell apoptosis. To 
simplify the analysis, we examined the effects on T-lymphocytes of a single dose of 
dexamethasone. 
2. Experimental 
2.1. Animals 
Lewis rats (JC strain; 20 female, 167 male), aged 8–10 weeks, were obtained from the animal 
breeding facility of The University of Queensland. 
2.2. Preparation of inoculum and induction of EAE 
MBP was prepared from guinea pig brains by the method of Deibler et al., 1972. MBP in 
0.9% saline was emulsified in an equal volume of incomplete Freund's adjuvant (CSL, 
Melbourne, Australia) containing 4 mg/ml Mycobacterium butyricum (Difco). Under 
anaesthesia, rats were inoculated in one hind footpad with 0.1 ml emulsion. The total dose of 
MBP was 50 g per rat. 
2.3. Clinical assessment 
Rats were examined every morning. Weakness was assessed using the system of Pender 
(1986). Tail weakness was assessed by holding the animal by the base of the tail and 
observing tail movement. It was graded as follows: 0=no weakness; 1=weakness of the distal 
part of the tail only, the distal tail failing to curl around the examiner's finger; 2=weakness of 
the whole tail but with the proximal tail still able to be erected vertically against gravity; 
3=severe weakness with only a flicker of tail movement; 4=complete flaccid paralysis of the 
tail. Hindlimb weakness was graded as follows: 0=no weakness; 1=slight dragging of toes of 
both hindfeet; 2=severe dragging of both hindfeet but not the rest of the hindlimbs; 3=severe 
dragging of both hindlimbs, often with both hindlimbs displaced to one side of the body; 
4=total flaccid paralysis of the hindlimbs. The forelimbs were assessed in a similar way to the 
hindlimbs. The scores for the tail, hindlimbs and forelimbs were added to obtain a total 
clinical score (maximum=12). 
2.4. Dexamethasone or saline treatment 
Dexamethasone (David Bull Laboratories, Mulgrave, Victoria) was administered by 
subcutaneous injection at a dose of 4 mg/kg. Control rats were given the same volume of 
normal saline or were untreated. In a small clinical study of the effects of daily 
dexamethasone treatment, rats were given daily dexamethasone or saline injections for 5 days 
from the day of onset of signs. For the limiting dilution and flow cytometry studies, rats were 
given a single dose of dexamethasone or saline, 1–12 h before study on the morning of day 12 
or day 14 after inoculation. 
2.5. Extraction of cells from the spinal cord 
Cells were extracted from the pooled spinal cords of groups of rats that had been untreated, 
saline-treated or dexamethasone-treated. As shown in Table 1, 2–6 groups of rats were 
studied for each type of treatment. Using our previously described methods (Tabi et al., 
1994), cells were isolated from the spinal cords of rats perfused with ice-cold saline under 
anaesthesia. The entire spinal cords were removed by insufflation and weighed, and a single 
cell suspension of the pooled spinal cords in ice-cold RPMI containing 1% foetal calf serum 
was prepared by passage through a 200-mesh stainless steel sieve. The cell suspension was 
mixed with isotonic Percoll (Percoll:HBSS 9:1) in a 3:2 ratio (density 1.052) in 50 ml 
centrifuge tubes and spun for 25 min at 640×g at 4°C. The cell pellet and the last 9 ml 
supernatant were resuspended, transferred to a conical centrifuge tube, underlaid with 1 ml 
Ficoll, and spun for 20 min at 600×g at 4°C. The cells from the interface above the Ficoll 
were collected, washed and counted. The cells were then passed through a nylon wool 
column.  
 
2.6. Monoclonal antibodies 
Mouse monoclonal antibodies specific for CD5 (OX19), the T-cell receptor (R73) and 
CD45 (OX1) were obtained from Dr J. Sedgwick (Sydney, Australia). Antibody to V 8.2 
(Torres Nagel et al., 1993) was kindly provided by Dr T. Hünig (Würzburg, FRG). Mouse 
IgG1 (Dako) was used as an isotype control antibody. The secondary antibody was 
fluoroscein isothiocyanate (FITC)-conjugated F(ab′)2 rabbit anti-mouse IgG (STAR 41) 
(Serotec). 
2.7. Labelling of cells and flow cytometric analysis 
Using our previously described methods (Tabi et al., 1994), cells were labelled with 
monoclonal antibodies or permeabilized and labelled with propidium iodide for analysis of 
apoptosis according to the method described by Telford et al. (1991). Briefly, aliquots of 105–
106 cells were washed with a 1:1 solution of serum in phosphate-buffered saline (PBS) 
containing 1% foetal calf serum and 0.1% sodium azide, incubated with primary antibodies in 
PBS/azide for 30 min at 4°C. Cells were washed, incubated with secondary antibody for 30 
min at 4°C in the dark and then washed twice with PBS to remove proteins in solution. Cells 
were resuspended in 1 ml of ice-cold 50% ethanol and left to fix overnight at 4°C. The 
following day, the ethanol was removed by washing the cells in PBS, and the cell pellets were 
resuspended in an appropriate volume (100–300 l) of propidium iodide staining solution 
(freshly prepared by diluting stock solution [5 mg/ml RNase/250 g/ml propidium iodide in 
0.1 M PBS, pH 7.4/0.1 mM EDTA] 1:4 with PBS/azide). Samples were kept on ice, in the 
dark, and analysed using a Becton Dickinson FACScan within 1 h. 
Flow cytometric data was analyzed using Lysis II Software (Becton Dickinson). The 
percentage of antibody-positive cells was determined from histograms of FITC fluorescence 
intensity. Background fluorescence, obtained by labelling the cells with isotype control 
antibodies and FITC, was subtracted from the test values. To analyse levels of apoptosis, 
histograms of propidium iodide fluorescence were obtained. Debris with low levels of 
fluorescence was excluded by gating. Apoptotic events were defined as those having lower 
fluorescence than the sharply defined G0/G1 peak (Telford et al., 1991). We have previously 
shown by cell sorting that cells with low propidium iodide fluorescence characteristic of 
apoptosis also have DNA fragmentation characteristic of apoptosis. When there were many 
apoptotic events, the G0/G1 peak was defined in control samples. 
2.8. Enrichment of V 8.2+ cells in the apoptotic lymphocyte 
populations 
To estimate the selectivity of apoptosis of V 8.2+ T-cells, we compared the percentage of 
apoptotic T-lymphocytes that were V 8.2+ to the percentage of non-apoptotic T-lymphocytes 
that were V 8.2+ using our previously described methods (Tabi et al., 1994; McCombe et al., 
1996). This comparison was expressed as a mean ratio for each type of treatment and 
represents the enrichment of V 8.2+ cells in the apoptotic lymphocyte populations. We 
assumed that the V 8.2+ cells in the CNS in EAE are CD5+ and TCR +. For each group of 
rats that had received similar treatment, the ratios of the percentage of apoptotic cells that 
were V 8.2+ to the percentages of apoptotic cells that were CD5+ or TCR + were 
calculated. In a similar fashion, the ratios of the non-apoptotic cells that were V 8.2+ to the 
percentages of non-apoptotic cells that were CD5+ or TCR + were calculated. The 
enrichment of V 8.2+ cells in the apoptotic compared to the non-apoptotic T-cell population 
was then calculated by dividing the ratio for the apoptotic cells by the ratio for the non-
apoptotic cells. For each type of treatment, we then calculated the mean enrichment. 
2.9. Limiting dilution analysis 
A suspension of cells was prepared from the spinal cord as described above. Plastic adherent 
cells were removed by incubating the CNS cell suspensions at 105–106 cells/ml in 100 mm 
diameter polystyrene Petri dishes (Corning) for 45 min at 37°C. Non-adherent cells were 
collected by vigorously pipetting the cells and rinsing the dishes with RPMI 1640 
supplemented with 216 mg/l -glutamine (Gibco), 100 IU penicillin, 100 g/ml streptomycin 
(Sigma), 0.1 mM Na-pyruvate (Gibco), non-essential amino acids (Gibco), 36 mg/l -
asparagine (Sigma), 5×10−5 M -mercaptoethanol (Sigma), 5 g/ml Fungizone (Squibb) and 
5% heat-inactivated horse serum (Trace Biosciences). Limiting dilution analysis was carried 
out as previously described (Tabi et al., 1995). Briefly, 12–24 replicates of increasing 
numbers of cells extracted from the CNS and 5×105 irradiated thymic cells as antigen-
presenting cells were incubated with 15 g/ml MBP, 50 U/ml mouse recombinant interleukin-
2 (IL-2) (Boehringer Mannheim) or 5 g/ml Concanavalin-A (Con-A) (Sigma). Control wells 
contained the same numbers of spinal cord cells as the MBP or IL-2 stimulated wells and 
5×105 irradiated thymic cells in the absence of antigen or mouse recombinant IL-2. For the 
Con-A stimulated proliferation, the control wells contained irradiated thymic cells alone with 
Con-A. MBP and IL-2 stimulated wells and their controls were supplemented with 10 U/ml 
IL-2 (MLA 144 supernatant) 24 h after the commencement of the assay and were incubated 
for 7 days. Con-A stimulated cultures and their controls were not supplemented with IL-2 and 
were incubated for 5 days. For the last 12 h of incubation, 3H-thymidine was added to the 
wells. Wells were scored as positive if the thymidine incorporation was at least twice 
background. 
3. Results 
3.1. Clinical effects of daily dexamethasone treatment 
Rats with MBP–EAE that were given daily injections of dexamethasone from the day of onset 
of signs had less severe clinical signs and earlier onset of clinical recovery than rats treated 
with daily saline injections. 
3.2. Clinical effects of a single dose of dexamethasone prior to 
study on day 12 or day 14 
The clinical scores of rats used for the flow cytometry study are shown in Table 1. The rats 
were examined on the morning of each day and the clinical scores are shown for the day 
before study and the day of study. Dexamethasone injections were given 1–12 h before 
sacrifice for study on the mornings of day 12 or 14 after inoculation. Treatment with 
dexamethasone 12 h prior to day 12 appeared to reduce the progression of clinical signs of 
disease from day 11 to day 12. Treatment with dexamethasone 12 h prior to day 14 did not 
arrest progression of clinical signs of disease from day 13 to day 14. 
3.3. Numbers of lymphocytes in the spinal cord after 
dexamethasone treatment 
The numbers of lymphocytes in the spinal cords of rats were studied on days 12 and 14 at 
varying times after a single dose of dexamethasone, after saline treatment or after no 
treatment. On day 12 (see Fig. 1), rats that had been treated 12 h previously with 
dexamethasone (4 mg/kg) had few CD5+ cells and few V 8.2+ cells in the spinal cord 
compared to those that had received no treatment or had received saline 12 h previously.  
 
 
Fig. 1. Numbers of CD5+ and V 8.2+ cells/g of spinal cords of rats on day 12 after inoculation with 
MBP and adjuvants. The numbers of lymphocytes were measured by flow cytometry. 12 h prior to 
study on the morning of day 12, rats were given no treatment, saline treatment or dexamethasone (4 
mg/kg) treatment (dex=dexamethasone). 
 
In rats studied on day 14, we compared the effects of no prior treatment, treatment with saline 
12 h previously and treatment with dexamethasone 1, 2, 3, 4, 8 and 12 h prior to study. Fig. 2 
shows the numbers of CD5+ cells, TCR + cells and V 8.2+ cells in untreated rats, rats 
treated with dexamethasone and rats treated with saline. The numbers of CD5+ cells, TCR + 
cells and V 8.2+ cells had declined considerably by 8 h after dexamethasone treatment. At 
earlier time points (1–4 h), the decline mainly affected the V 8.2+ population. 
 
 
 
Fig. 2. Numbers of CD5+, TCR + and V 8.2+ cells/g of spinal cord of rats on day 14 after 
inoculation with MBP and adjuvants. The numbers of lymphocytes were measured by flow cytometry. 
Rats were given no treatment, saline treatment 12 h prior to study, or dexamethasone treatment 1–12 h 
prior to study on day 14 (dex=dexamethasone). 
3.4. Limiting dilution analysis of lymphocyte frequencies in the 
spinal cord after treatment with dexamethasone 
The frequency of MBP-reactive cells was studied on days 12 and 14. Table 2 shows the 
frequencies of cells in groups of rats, studied on day 12, that had been given saline or 
dexamethasone 12 h previously. After dexamethasone treatment there was a major decline in 
the frequency of MBP-reactive cells while the frequency of Con-A-responsive cells remained 
relatively high. The frequency of IL-2-responsive cells also declined considerably after 
dexamethasone treatment. We performed a similar study on day 14 and found that the 
frequency of MBP-reactive cells in a saline-treated rat was 1/19703, while in a 
dexamethasone-treated rat it was 1/114262.  
 
 
 
3.5. Numbers of apoptotic cells in the spinal cord after treatment 
with dexamethasone 
The studies detailed above indicate that corticosteroid treatment results in a reduction in the 
number of T-lymphocytes in the spinal cord of rats with EAE. To determine whether the 
reduction in cell numbers was associated with increased levels of apoptosis, we used flow 
cytometry to measure numbers of apoptotic cells. We were unable to perform these studies on 
day 12, because insufficient cells remained after dexamethasone treatment to permit analysis 
of apoptosis. The percentages, on day 14, of all the cells extracted from the spinal cord that 
were apoptotic in untreated rats, dexamethasone-treated rats and saline-treated rats are shown 
in Fig. 3. The percentages of cells that were apoptotic were increased in the rats given 
dexamethasone 1–12 h prior to study compared to the untreated and saline-treated animals. 
Fig. 4 shows the percentage of cells of different types that were apoptotic in untreated rats and 
in rats given prior treatment with dexamethasone or saline. In untreated rats and in saline-
treated rats, the percentages of V 8.2+ cells that were apoptotic were greater than the 
percentages of CD5+ and TCR + cells that were apoptotic, indicating that there is selective 
apoptosis of the disease-relevant V 8.2+ cells in this form of EAE, as we have shown 
previously (McCombe et al., 1996). One to 8 h after dexamethasone treatment there were 
increases in the percentages of CD5+ cells and TCR + cells that were apoptotic. The 
percentage of V 8.2+ cells that were apoptotic was decreased 1–4 h after dexamethasone but 
was increased at 8–12 h.  
 
Fig. 3. Percentages of the cells extracted from the spinal cord that were apoptotic on day 14 after 
inoculation of rats with MBP and adjuvants. Rats were given no treatment, saline treatment 12 h prior 
to study, or dexamethasone treatment 1–12 h prior to study on day 14. In the rats that received 
dexamethasone treatment 1–12 h prior to study, the percentages of cells that were apoptotic were 
increased compared to the untreated and saline-treated rats (dex=dexamethasone). 
 
 
Fig. 4. Percentages of CD5+, TCR + V 8.2+ cells that were apoptotic in the spinal cord of rats 
studied on day 14 after inoculation with MBP and adjuvants. Rats were given no treatment, saline 
treatment 12 h prior to study, or dexamethasone treatment 1–12 h prior to study on day 14 
(dex=dexamethasone). 
 
To analyse further the effects of dexamethasone on the selective apoptosis of V 8.2+ cells, 
we calculated the enrichment of V 8.2+ cells in the apoptotic, compared to the non-apoptotic 
CD5+ and TCR + populations (Fig. 5). In untreated rats and in saline-treated rats, there was 
a 2–3 fold enrichment of V 8.2+ cells in the apoptotic population, once again indicating 
selective apoptosis of these disease-relevant cells. At 1–4 h after dexamethasone treatment the 
enrichment of V 8.2+ cells in the apoptotic populations was reduced to a level of unity (that 
is, no enrichment). By 8–12 h the enrichment was restored to that observed in saline-treated 
controls. 
 
 
Fig. 5. Enrichment of V 8.2+ cells in the apoptotic CD5+ and TCR + populations of cells from the 
spinal cords of rats studied on day 14 after inoculation with MBP and adjuvants. Rats were given no 
treatment, saline treatment 12 h prior to study, or dexamethasone treatment 1–12 h prior to study on 
day 14 (dex=dexamethasone). 
 
Fig. 6 shows the numbers of cells of different types that were apoptotic on day 14 at 
different times after dexamethasone treatment. In rats given dexamethasone 1–4 h 
previously, there was an increase in the number of apoptotic CD5+ cells and a 
decrease in the number of apoptotic V 8.2+ cells. The number of apoptotic TCR + 
cells was increased 4 h after dexamethasone treatment. At 8 and 12 h after 
dexamethasone treatment, the numbers of CD5+, TCR + and V 8.2+ apoptotic cells 
were all reduced, reflecting the reduced numbers of cells remaining in the CNS (see 
Fig. 2). 
 
 
 
Fig. 6. Numbers of apoptotic CD5+, TCR + and V 8.2+ cells/g of spinal cord of rats studied at day 
14 after inoculation with MBP and adjuvants. Rats were given no treatment, saline treatment 12 h prior 
to study, or dexamethasone treatment 1–12 h prior to study on day 14. (dex=dexamethasone). 
 
4. Discussion 
The development of EAE in Lewis rats is associated with infiltration of the nervous system by 
T-lymphocytes and macrophages (Hickey et al., 1983; McCombe et al., 1992), followed by 
demyelination of the central nervous system and the nerve roots. We have recently shown that 
recovery from passively transferred and actively induced MBP–EAE is associated with a 
selective elimination of V 8.2+ MBP-reactive T-cells from the spinal cord by apoptosis (Tabi 
et al., 1994 and Tabi et al., 1995; McCombe et al., 1996) and have suggested that this 
apoptosis may represent activation-induced cell death of T-lymphocytes in the target organ of 
this autoimmune disease (Pender et al., 1992; Tabi et al., 1994 and Tabi et al., 1995). 
In the present experiments, we have studied the effects of corticosteroids on T-cells in the 
nervous system in EAE. Endogenous corticosteroid production is thought to be important in 
spontaneous recovery from EAE (Levine et al., 1980; MacPhee et al., 1989). Therapy with 
exogenous corticosteroids has also been shown to be of clinical benefit in EAE (Kibler, 1965; 
Vogel et al., 1972). We found that daily high-dose corticosteroid treatment of rats with MBP–
EAE leads to less severe clinical signs and earlier recovery from signs of disease. To simplify 
the assessment of the effects of exogenous dexamethasone on the T-cells in the CNS in MBP–
EAE, we used rats treated with a single dose of dexamethasone. In these rats there was a 
reduction in the numbers of T-lymphocytes, including V 8.2+ and MBP-reactive 
lymphocytes, in the spinal cord. Such corticosteroid-induced reduction in T-cell infiltration of 
the nervous system could lead to clinical benefits by reducing ongoing demyelination, thus 
allowing the remyelination which normally occurs during recovery from EAE (Pender, 1989) 
to restore neurological functions. 
The action of glucocorticoids is mediated by a cytoplasmic receptor molecule that enters the 
nucleus and has multiple effects on gene activation (de Waal, 1994). Corticosteroids have 
many effects on inflammation and immune function, such as effects on vascular endothelium, 
adhesion molecule expression, cytokine production, T-cell activation and T-cell apoptosis (de 
Waal, 1994). The number of T-lymphocytes in the CNS at any time will be influenced both 
by the entry of new cells into the CNS, by apoptosis of T-lymphocytes within the CNS and by 
the exit of lymphocytes from the CNS. Thus, the reduction in the numbers of lymphocytes in 
the CNS in EAE after corticosteroid treatment could result from a number of different 
mechanisms, including peripheral effects on T-cell activation, reduction of entry of T-
lymphocytes into the CNS and by increased T-cell apoptosis. Because of the importance of T-
cell apoptosis in the CNS in spontaneous recovery from EAE, we studied the effects of 
corticosteroids on apoptosis. We measured apoptotic cells in the CNS after dexamethasone 
treatment and found that the percentage of T-lymphocytes that were apoptotic was increased 
compared to controls. We did not attempt to assess peripheral effects of dexamethasone. 
Corticosteroids are known to cause apoptosis of mature T-lymphocytes in vitro (Nieto and 
Lopez-Rivas, 1989; Zubiaga et al., 1992; Tuosto et al., 1994), and an increase in T-
lymphocyte apoptosis in the CNS in EAE after dexamethasone treatment is consistent with 
these known effects of corticosteroids. 
After corticosteroid treatment there was an early decline in the percentage of V 8.2+ cells 
that were apoptotic and in the number of apoptotic V 8.2+ cells in the CNS. Furthermore, at 
1–4 h after dexamethasone treatment, V 8.2+ cells were not selectively eliminated by the 
apoptotic process, as they are during spontaneous recovery from EAE. Therefore, the early 
reduction in the number of V 8.2+ cells in the CNS cannot be explained by increased 
apoptosis of these cells. The marked reduction in the number of V 8.2+ cells and in the 
frequency of MBP-reactive cells in the CNS after dexamethasone treatment may result from 
reduced entry of these cells into the CNS or from their increased exit. By 8–12 h after 
dexamethasone treatment the apoptotic elimination of V 8.2+ cells was again selective. 
We have suggested that the T-cell apoptosis that occurs during spontaneous recovery from 
EAE is due to activation-induced apoptosis which is dependent on engagement of the T-cell 
receptor in the CNS (Pender et al., 1992; Tabi et al., 1994 and Tabi et al., 1995). 
Glucocorticoids antagonize activation-induced apoptosis, probably by reducing the expression 
of the Fas ligand (Zacharchuk et al., 1990; Iseki et al., 1991; Yang et al., 1995), and we 
suggest that such an effect occurs after corticosteroid treatment of EAE and explains the 
reduction in the selective apoptosis of V 8.2+ cells. Indeed, the observation that the selective 
apoptosis of V 8.2+ cells is steroid-sensitive is support for the suggestion that this apoptosis 
is activation-induced. 
This study of corticosteroid treatment of EAE may have implications for the treatment of 
multiple sclerosis. High dose methylprednisolone therapy accelerates recovery from relapses 
of multiple sclerosis (Durelli et al., 1986; Milligan et al., 1987). In optic neuritis, low-dose 
oral prednisone does not accelerate clinical recovery and may lead to an increased risk of 
relapse, whereas treatment with high dose methylprednisolone accelerates recovery and may 
reduce the risk of relapse (Beck et al., 1992). The present study suggests that corticosteroid 
treatment may temporarily inhibit the selective apoptosis of disease-producing T-cells in the 
CNS in inflammatory demyelinating disease. It is not known whether apoptosis of disease-
causing T-cells occurs in the CNS in multiple sclerosis. Indeed, we have hypothesized that a 
failure of this mechanism may predispose to the development of chronic autoimmune disease 
(Tabi et al., 1995). However, if activation-induced apoptosis of disease-producing T-cells in 
the CNS has a role in recovery from episodes of multiple sclerosis, impairment of such 
apoptosis by corticosteroid therapy would be undesirable. The dose and timing of 
corticosteroid therapy might then be important in determining whether this therapy is 
beneficial or harmful in multiple sclerosis.  
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